NCT07785154 A Registry-study of ELZONRIS in Participants With BPDCN
| NCT ID | NCT07785154 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stemline Therapeutics, Inc. |
| Condition | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-06-26 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2024-06-26 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
Eligibility Criteria
Key Inclusion Criteria: * Diagnosed with BPDCN, confirmed by hematopathology and biomarkers (inclusive of CD123, CD4, and CD56). * Planning to start treatment with tagraxofusp monotherapy for BPDCN at the time of, or within 6 months prior to, informed consent form (ICF) signature or has started treatment. Key Exclusion Criteria: * Currently (or planning to) participating in another study or registry where BPDCN treatment outcomes are reported. * Participating in an interventional clinical trial at the time of ICF signature. * Known allergic reactions to components of tagraxofusp. Note: Other protocol-specified criteria apply.
Contact & Investigator
Medical Director
STUDY DIRECTOR
Stemline Therapeutics, Inc.
Frequently Asked Questions
Who can join the NCT07785154 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07785154 currently recruiting?
Yes, NCT07785154 is actively recruiting participants. Contact the research team at clinicaltrials@menarinistemline.com for enrollment information.
Where is the NCT07785154 trial being conducted?
This trial is being conducted at Innsbruck, Austria, Linz, Austria, Salzburg, Austria, Vienna, Austria and 11 additional locations.
Who is sponsoring the NCT07785154 clinical trial?
NCT07785154 is sponsored by Stemline Therapeutics, Inc.. The principal investigator is Medical Director at Stemline Therapeutics, Inc.. The trial plans to enroll 80 participants.